Preferred Label : lanreotide;

MeSH note : somatostatin analogue that suppresses GH/IGF-I hypersecretion in acromegaly patients and used to manage neuroendocrine tumours; do not confuse with BIM 23014 C; amino acid sequence given in first source;

CISMeF synonym : 188Re-lanreotide; BIM 23014; DC 13-116; lanreotide-SR; lasa brand of lanreotide acetate; somatulin; somatulina; somatuline;

MeSH synonym : naphthalenyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)threoninamide; L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide; naphthyl-cyclo(Cys-Tyr-Trp-Lys-Val-Cys)Thr-NH2; Nal-cyclo(Cys-Tyr-Trp-Lys-Val-Cys)Thr-NH2; 2-naphthylalanyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)-threoninamide; Nal-cyclo(Cys-Tyr-Trp-Lys-Val-Cys)-Thr-NH2; 3-(2-naphthyl)alanyl-cystinyl-tyrosyl-tryptophyl-lysyl-valyl-cystinyl-threonine amide; D-Nal-Cys-Tyr-Trp-Lys-Val-Cys-Thr-NH2; angiopeptin; 3-(2-naphthyl)-D-Ala-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;

MeSH hyponym : BIM-23014; DC13-116; DC-13-116; BIM 23014C; BIM-23014 C;

MeSH CAS label : L-Threoninamide, 3-(1-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide;

MeSH Related Number : lanreotide acetate; 127984-74-1; 118992-92-0 (lanreotide); 127984-74-1 (lanreotide acetate); IEU56G3J9C;

Registry Number MeSH : 118992-92-0;

Related CAS MeSH : 127984-74-1 (lanreotide acetate);

related registry number list (CISMeF) : 127984-74-1;

Is substance : O;

UNII : 0G3DE8943Y;

Details


Main resources

You can consult :


http://www.has-sante.fr/portail/jcms/c_2625989/fr/somatuline-lp
2016
false
France
French
gastro-enteropancreatic neuroendocrine tumor
lanreotide acetate
lanreotide
injections
Delayed-Action preparations
peptides, cyclic
somatostatin
lanreotide
antineoplastic agents
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
intestinal neoplasms
pancreatic neoplasms
stomach neoplasms
neuroendocrine tumors

---
http://www.has-sante.fr/portail/jcms/c_2586912/fr/somatuline-lp
http://www.has-sante.fr/portail/jcms/c_1019676/somatuline-lp
2015
false
France
French
Thyrotroph Pituitary Neuroendocrine Tumor
lanreotide
injections
Delayed-Action preparations
peptides, cyclic
somatostatin
lanreotide
acromegaly
antineoplastic agents
carcinoid tumor
treatment outcome
insurance, health, reimbursement
pituitary neoplasms
evaluation of the transparency committee

---
http://www.meddispar.fr/medicaments/3572889
2008
France
French
Delayed-Action preparations
somatostatin
peptides, cyclic
injections
drug prescriptions
legislation, drug
lanreotide
lanreotide
drug information

---
http://www.meddispar.fr/medicaments/3572895
2008
France
French
somatostatin
pharmaceutical solutions
injections
peptides, cyclic
Delayed-Action preparations
lanreotide
lanreotide
drug information

---
http://www.meddispar.fr/medicaments/3572872
2008
France
French
somatostatin
pharmaceutical solutions
injections
peptides, cyclic
Delayed-Action preparations
drug prescriptions
legislation, drug
lanreotide
lanreotide
drug information

---
http://www.meddispar.fr/medicaments/3373523
2008
France
French
peptides, cyclic
somatostatin
suspensions
injections, intramuscular
Delayed-Action preparations
drug prescriptions
legislation, drug
lanreotide
lanreotide
drug information

---
SUMMARY BASIS OF DECISION (SBD): SOMATULINE AUTOGEL
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00137
2007
false
Canada
English
French
lanreotide
lanreotide
peptides, cyclic
peptides, cyclic
somatostatin
somatostatin
injections, subcutaneous
growth inhibitors
growth inhibitors
lanreotide
acromegaly
Delayed-Action preparations
drug information
package leaflet

---
https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Somatuline-Autogel_July-19-2007_f.pdf
2007
Canada
French
acromegaly
antineoplastic agents
somatostatin
peptides, cyclic
lanreotide
lanreotide
drug evaluation

---
Nous contacter.
16/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.